Abstracts non-small-cell lung cancer (NSCLC) using gefi tinib or docetaxel. Probability distributions for adverse events and life expectancy were obtained from the INTEREST study. We used a docetaxel chemotherapy cost-study at ISSSTE and for gefi tinib we used the drug's institutional price. Health state utility values for calculating QALYs (Quality Adjusted Life Years) were derived from a recently published study done with UK patients. A 3% annual discount rate was applied on a monthly basis to all costs. Finally, a probabilistic sensitivity analysis was made varying the cost of chemotherapy. The model was run 25 times with 500 patients in each arm. Results are presented in US dollars with an exchange rate of 13.5 MXN pesos for 1 US dollar. RESULTS: There was no clinical difference in life expectancy between gefi tinib (10.25 months) and docetaxel (10.14 months). Average QALY for gefi tinib cohort was 0.487 (95% CI, 0.437 -0.537) and for chemotherapy cohort was 0.438 (95% CI, 0.388 -0.488). The average cost per patient treated with gefi tinib was $12,103 (95% CI, $11,916 -$12,290) and with docetaxel was $20, 076 (95% CI, $19,286). The acceptability curve shows a 100% dominace of gefi tinib over docetaxel, after a chemotherapy price of $1,333. CONCLUSIONS: Gefi tinib is an alternative therapy for second line treatment of NSCLC that dominates docetaxel chemotherapy, in terms of quality of life related to reduced presence of adverse events, at a lesser cost to the institution.
PCN74 COST UTILITY OF POSACONAZOLE VERSUS FLUCONAZOLE/ ITRACONAZOLE THERAPY IN THE PROPHYLAXIS AGAINST INVASIVE FUNGAL INFECTIONS AMONG HIGH-RISK NEUTROPENIC PATIENTS IN MEXICO
Rely K y 1 , Pierre KA 2 , Salinas EG 3 1 Network on the Economic Evaluation of Healthcare Programmes and its Applications to Decision Making in Latin American Countries, Mexico, DF, Mexico, 2 Johns Hopkins University, 2 Bloomberg School of Public Health, Baltimore , MD, MD, USA, 3 Hospital Infantil de México Federico Gómez, Mexico, DF, Mexico OBJECTIVES: To estimate the cost effectiveness of Posaconazole versus fl uconazole/ itraconazole therapy in the prophylaxis against invasive fungal Infections among highrisk neutropenic patients in Mexico. METHODS: A previously validated Markov model was used to compare the projected lifetime costs and effects of two theoretical groups of patients, one receiving Posaconazol and the other receiving fl uconazole/itraconazole. The model estimates total costs, numbers of IFIs, and QALY per patient in each prophylaxis group. The model was extended with one-month Markov cycles in which mortality risk is specifi c to the underlying disease. Data on the probabilities of IFI were obtained from Study Protocol PO1899. Drug costs were taken from average wholesale drug reports for 2008. Cost and health effects were discounted at 5%. The analysis was conducted from the Mexican health care perspective using 2008 unit cost prices. RESULTS: Our model projects an accumulated cost to the Mexican health care system per patient receiving the Posaconazol regimen of US$7463 compared to US$5634 for the fl uconazole/itraconazole regimen. This results in an incremental cost of -(US$1829) per patient. The accumulated discounted effect is 3.13 life years or 2.25 quality adjusted life years (QALYs) per patient receiving Posaconazol, compared to 3.13 life years or 2.13 QALYs per patient receiving fl uconazole/itraconazol. This translates into an incremental effect of posaconazole over fl uconazole/itraconazole of 0.17 life years gained (LYG) or 0.12 QALYs gained. The corresponding incremental cost effectiveness ratio (iCERs) is -(US$15,125) per QALY. Probabilistic sensitivity analysis tested numerous assumptions about the model cost and effi cacy parameters and found that the results were robust to most changes. CONCLUSIONS: The use of temozolomide in place of fl uconazole/itraconazole for the prophylaxis against invasive fungal Infections among high-risk neutropenic patients is likely to be cost saving. These conclusions are supported by the use of conservative assumptions and sensitivity analyses.
PCN75 THE IMPACT OF NEUTROPENIC COMPLICATIONS ON SHORT-TERM DISABILITY IN PATIENTS WITH CANCER RECEIVING CHEMOTHERAPY
Song X g 1 , Fowler R 2 , McGuffi e K 2 , Hurley D 3 , Barron RL 3 1 Thomson Reuters, Cambridge, MA, USA, 2 Thomson Reuters, Washington, DC, USA, 3 Amgen, Inc., Thousand Oaks, CA, USA OBJECTIVES: Patients receiving myelosuppressive chemotherapy are at risk for chemotherapy-induced neutropenic complications (CINC). The study objective was to examine the impact of CINC, defi ned as neutropenia with fever or infection, on shortterm disability (STD) among cancer patients receiving chemotherapy. METHODS: Patients with cancer undergoing chemotherapy were extracted from Thomson Reuters MarketScan Commercial Database and Health and Productivity Management Database. Patients were required to have at least 6 months continuous enrollment before the index date (fi rst chemotherapy claim) and at least 30 days continuous enrollment post-index date, full-time employment and eligibility for STD. Patients with ICD-9 codes for neutropenia and fever or infection and that had evidence of chemotherapy within 30 days prior were defi ned as having CINC. Propensity score (PS) matching was conducted for "CINC" and "non-CINC" patients based on demographic and clinical characteristics, including chemotherapy class and use of highly myelosuppressive chemotherapeutic agents. Subsequent multivariate regressions were conducted on PS-matched cohorts to estimate the marginal impact of CINC: an Ordinary Least Squares Model on STD days, a generalized linear model on indirect cost associated with STD, and a logistic regression model on whether a patient used any STD days during a month. RESULTS: A total of 280 CINC and 280 non-CINC patients were PS-matched. Compared with matched non-CINC patients, CINC patients on average experienced 0.9 more STD day (3.2 vs. 2.3, p 0.046) which led to $156 more in indirect costs ($549 vs. $394, p 0.050) per month. After multivariate adjustment, CINC patients were 35% (p 0.121) more likely to experience at least one STD day, experienced 1.0 more STD day (p 0.029), and incurred $200 more in indirect cost (p 0.016) per month. CONCLUSIONS: Patients with CINC experience signifi cantly greater STD days than patients with no neutropenic complications from cancer chemotherapy. Efforts that may prevent CINC can potentially have a benefi cial impact on work absenteeism.
PCN76 REVISITING CHERNOBYL: THE LONG-RUN IMPACT OF THE NUCLEAR ACCIDENT ON LABOR MARKET OUTCOMES
Zelenska T Georgia State University, Atlanta, GA, USA OBJECTIVES: The accident at the Chernobyl nuclear power plant in 1986 released an enormous amount of radioactive materials which spread over the territories of Ukraine, Belarus, Russia and other European countries. The damage caused to the environment, economy and, most importantly, to human health has been challenging to estimate. In fact, there is no scientifi c agreement on the severity of the Chernobyl aftermath. The purpose of our paper is to investigate the long-run impact of the tragedy on the labor market outcomes of the Ukrainian population. METHODS: Specifi cally, using data from 2001 household survey and a self-reported measure of well-being, we estimate the impact of the Chernobyl accident on individual earnings. In addition, we identify a substantial gender wage gap existing in the Ukrainian labor markets. We use the Oaxaca decomposition technique to examine the wage gap in more detail. RESULTS: We fi nd that those individuals whose health has suffered as a result of the accident receive on average 5% lower wages, after controlling for other characteristics. CONCLUSIONS: We fi nd that a large portion of the wage gap is "unexplained" and may be attributed to discrimination against women; in addition, the health effects of the Chernobyl accident explain a signifi cant portion of the gender wage inequality.
PCN77 HEALTH CARE RESOURCE UTILIZATION ASSOCIATED WITH ESCALATING IMATINIB VERSUS SWITCHING TO DASATINIB IN PATIENTS WITH CHRONIC MYELEGENOUS LEUKEMIA
Yu AP 1 , Guo A 2 , Guérin A 1 , Latremouille-Viau D 1 , Tsaneva M 1 , Xie J 1 , Signorovitch J 1 , Williams D 2 , Wu E 1 1 Analysis Group, Inc., Boston, MA, USA, 2 Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA OBJECTIVES: After initial therapy with imatinib, chronic myelogenous leukemia (CML) patients who do not completely respond may require dose escalation or switching to another BCR/ABL kinase inhibitor to achieve the desired response. This study compared health care resource utilization associated with either escalation of imatinib dose or switching to dasatinib. METHODS: Two large administrative claims databases were combined (MarketScan and Ingenix Impact, January 1999-March 2008) to identify patients diagnosed with CML (ICD-9 code: 205.1). Patients initiated with imatinib who were continuously enrolled 6 months prior to and at least one month following their fi rst dose increase or switch to dasatinib were selected. Patients who switched to dasatinib before reaching imatinib 800 mg/day (switchers) and the non-
